Lai: Metabolically related fatty liver disease indications for peptide therapy breakthrough.

On January 29th, according to information from Eli Lilly, the National Medical Products Administration Drug Evaluation Center announced that Metformin Mufengda for the treatment of metabolic associated fatty liver disease has officially been added to the list of breakthrough therapies. Metabolic associated fatty liver disease is a multi-system disease related to systemic metabolism disorders, which can affect multiple important organs and lead to serious complications both inside and outside the liver.